Verified peer comparison

ABBV vs GILD

AbbVie Inc. compared with Gilead Sciences, Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

GILD

Gilead Sciences, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

ABBV: Biotechnology

GILD: Biotechnology

Upside lens

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

GILD: Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth. Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio. Livdelzi uptake can add a new growth leg alongside established antiviral franchises.

Risk lens

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.

GILD: Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions. Large acquisitions and acquired research charges can consume capital without producing approved products. Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.